αEvidence

前沿证据卡片 Frontier Evidence Cards

按最近更新日期排序。核查 2026-10-17。人类 26 / 动物 9。这些卡片转述公开研究,不构成诊疗,也不出售药品或营养品。 Sorted by latest update. Checked 2026-10-17. Human 26 / animal 9. These cards summarize published research. They are not diagnosis or treatment, and this site does not sell drugs or supplements.

人类试验 Human trials

左右滑动查看Swipe to see more

更新日期
Updated
项目简介
Project
状态
Status
最新进展
Latest
证据
Evidence
2026-10-08 Life Bio ER-100:眼部 OSK 表观重编程基因治疗(玻璃体腔给药)
Life Bio ER-100: ocular OSK epigenetic reprogramming gene therapy (intravitreal)
Life Bio · NCT07290244
I 期 / Phase 1 中期:3 人至 Day56 无严重不良事件,建议升剂量;2 人视野有初步信号
Interim: 3 pts to Day56 no SAE; DSMB escalate; 2 with early visual-field signals
公司中期披露 / company interim
2026-10-08 XPRIZE · RPRGAON-Progeria:韩国小分子 Progerinin,清 progerin
XPRIZE · RPRGAON-Progeria: Progerinin small molecule designed to clear progerin
XPRIZE
Milestone 2 健康人 I 期已完成;儿童 HGPS II 期(BCH)与密歇根成体 Werner II 期已开招
Healthy Phase 1 done; pediatric HGPS Phase 2 (BCH) and Michigan adult Werner Phase 2 recruiting
Asiae + NCT04512963 / NCT06775041 / NCT05847179
2026-09-21 Retro RTR242:口服液,健康人 SAD/MAD I 期(溶酶体再酸化;登记适应症栏早发型阿尔茨海默,非患者入组)
Retro RTR242: oral liquid, healthy SAD/MAD Phase 1 (lysosomal re-acidification; registry indication early AD, no patients enrolled)
Retro · ACTRN12625001274460
I 期 / Phase 1 澳大利亚扩剂量中;健康人 SAD/MAD,适应症栏为早发型阿尔茨海默
Dose escalation in Australia; healthy volunteers; indication field early-onset AD
ANZCTR
2026-09-10 英矽智能 Rentosertib:中国 IPF · TNIK 抑制剂
Insilico Rentosertib: China IPF · TNIK inhibitor
Insilico
III 期 / Phase 3 GENESIS-IPF-3 首例给药;约 47 中心 / 约 320 人;主终点 52 周 FVC
First patient dosed in GENESIS-IPF-3; ~47 sites / ~320 pts; primary endpoint 52-wk FVC
公司稿 + 登记 / company + registry
2026-09-10 XPRIZE · Longeveron:异体骨髓间充质干细胞 laromestrocel
XPRIZE · Longeveron: allogeneic MSC laromestrocel
Longeveron
Milestone 2 既往衰弱 IIb 6 分钟步行较安慰剂改善;决赛将测肌肉/认知/免疫,预计 2027 夏开招
Prior frailty IIb 6MWT vs placebo improved; finalist endpoints muscle/cognition/immunity; ~summer 2027 enroll
Cell Stem Cell
2026-09-01 BioViva:Klotho + hTERT 基因治疗专利路径
BioViva: Klotho + hTERT gene-therapy patent path
BioViva
专利 / Patent 美国专利覆盖年龄相关认知下降的基因递送方法
US patent covers gene delivery for age-related cognitive decline
专利公告 / patent notice
2026-08-20 XPRIZE · TIME TRAVELER:日本欧芹植物 EV 口服胶囊
XPRIZE · TIME TRAVELER: Japanese parsley plant-EV oral capsules
报道页 / report
Milestone 2 日本双盲安慰剂 8 周(UMIN000059942,约 55-69 岁);数值结果未公开
Japan DBPC 8-wk (UMIN000059942, ~55-69y); numerical results not public
UMIN
2026-08-19 Moderna/默沙东 intismeran:黑色素瘤个体化 mRNA 新抗原疗法
Moderna/MSD intismeran: personalized melanoma mRNA neoantigen therapy
Moderna
III 期读出 / Phase 3 readout INTerpath-001:RFS、DMFS 优于单用帕博利珠单抗(约 1137 人;中期 topline,HR 未披露)
INTerpath-001: RFS & DMFS better than pembrolizumab alone (~1137; interim topline, HR not disclosed)
公司 topline / company topline
2026-08-17 XPRIZE · Goda Lab:稀土改造「超级外泌体」靶向衰老细胞
XPRIZE · Goda Lab: rare-earth engineered 'super-exosomes' targeting senescent cells
东京大学 / UTokyo
Milestone 2 小鼠改善衰弱与体能;与东北大学医院筹备人体试验
Mouse frailty/physical gains; preparing human trial with Tohoku Univ Hospital
大学新闻 / univ news
2026-08-13 XPRIZE · RETRO-EPIGERNA:澳门 KYN 复合胶囊(中药 + 益生菌)
XPRIZE · RETRO-EPIGERNA: Macao KYN capsule (TCM + probiotics)
澳科大 / MUST
Milestone 2 靶向衰老相关 tRNA 修饰;半决赛小样本人体已做,配方未公开
Targets aging-related tRNA modification; small semi-final human study done; formula undisclosed
澳科大 / MUST
2026-08-11 XPRIZE · AgelessRx:远程 9 联药 + 抗阻与教练
XPRIZE · AgelessRx: remote 9-drug stack + resistance training & coaching
AgelessRx
Milestone 2 雷帕霉素、二甲双胍、纳曲酮、NAD、Tirzepatide 等;决赛约 235 人、双盲 12 个月
Rapamycin, metformin, naltrexone, NAD, Tirzepatide, etc.; ~235 DBPC 12 mo
AgelessRx + NCT
2026-08-11 XPRIZE · Johns Hopkins-Suninflam:抗 Galectin-3 单抗 SIF001
XPRIZE · Johns Hopkins-Suninflam: anti-Galectin-3 mAb SIF001
JH CAIR
Milestone 2 当前 I 期剂量爬坡(NCT07051629);健康长寿决赛细节未公开
Phase 1 dose escalation (NCT07051629); healthspan finalist details not public
JH + NCT
2026-08-11 XPRIZE · Minicircle:FST + Klotho 非病毒质粒腹脂注射
XPRIZE · Minicircle: FST + Klotho non-viral plasmid (abdominal fat)
Minicircle
Milestone 2 联合小样本试点(NCT07285629)已完成,公开疗效数字仍少
Combo small pilot (NCT07285629) completed; public efficacy numbers still scarce
NCT
2026-08-11 XPRIZE · Mitochondrial All Stars:elamipretide(SS-31)稳线粒体
XPRIZE · Mitochondrial All Stars: elamipretide (SS-31) mitochondrial stabilizer
Mighty/UW
Milestone 2 老年皮下试点后准备双盲安慰剂 RCT
After elderly SC pilot, preparing DBPC RCT
PR + NCT
2026-08-11 XPRIZE · NYC-Vita:雷帕霉素/拉米夫定 + 亚精胺 + 有监督运动
XPRIZE · NYC-Vita: rapamycin/lamivudine + spermidine + supervised exercise
Mount Sinai
Milestone 2 半决赛小试验已完成;扩展试验预计 2026 年底前后开招
Semi-final small study done; expanded trial ~late 2026 enroll
Sinai + NCT
2026-08-01 BioNTech BNT168:HIV RNA 疫苗(阴性与阳性受试者,含分析性停药探索)
BioNTech BNT168: HIV RNA vaccine (negatives & PLWH, includes ATI exploration)
NCT07698600
I 期 / Phase 1 美/南非招募中;尚无免疫原性或效力读出
US/South Africa recruiting; no immunogenicity or efficacy readout yet
CT.gov
2026-06-02 NewLimit:肝细胞表观重编程平台
NewLimit: hepatocyte epigenetic reprogramming platform
NewLimit
临床前 / Preclinical 约 4.35 亿美元 C 轮;计划 2027 年人体试验
~$435M Series C; plans 2027 first-in-human
融资公告 / financing
2026-05-22 Retro 其余管线:iPSC 细胞与组织重编程等
Retro other pipeline: iPSC cell & tissue reprogramming, etc.
Retro Science
临床前 / Preclinical 公开信息仍为临床前;人体登记以 RTR242 为准
Still publicly preclinical; human registry is RTR242
公司公开页 / company page
2026-03-30 R3 Bio:无脑克隆 / 全身替换愿景
R3 Bio: brainless clone / whole-body replacement vision
R3 Bio
未证实 / Unverified 媒体报道投资者路演愿景;公司称当前做细胞培养级平台
Media covers investor-pitch vision; company says current work is culture-scale platform
调查报道 / investigative press
2026-01-06 IAVI G004 / Moderna mRNA-1645:HIV germline 靶向(eOD + Core + N332-GT5)
IAVI G004 / Moderna mRNA-1645: HIV germline targeting (eOD + Core + N332-GT5)
NCT06694753
I 期 / Phase 1 2025-12 首剂;低剂量设计减皮肤反应;尚无公开读出
First dose Dec 2025; low-dose to cut skin AEs; no public readout yet
IAVI + CT.gov
2025-11-19 辉瑞季节性流感 modRNA 疫苗
Pfizer seasonal influenza modRNA vaccine
NEJM
III 期发表 / Phase 3 published 18-64 岁相对效力约 34.5% vs 灭活四价
Ages 18-64 relative efficacy ~34.5% vs inactivated QIV
同行评审 / peer-reviewed
2025-10-16 威斯津 WGc-0201:慢性乙肝治疗性 LNP-mRNA(华西)
WestGene WGc-0201: therapeutic LNP-mRNA for chronic HBV (West China)
NCT07051187
I 期 / Phase 1 剂量爬坡招募中;目标功能治愈,尚无人体疗效读出
Dose escalation recruiting; functional cure is design goal; no human efficacy readout yet
CT.gov
2025-10-09 Altos Labs:表观重编程与体外器官灌注平台
Altos Labs: epigenetic reprogramming & ex vivo organ perfusion platform
Altos
临床前 / Preclinical 体外器官上测试部分重编程等;尚无公开人体试验
Testing partial reprogramming on ex vivo organs; no public human trial yet
行业媒体 / trade press
2025-09-01 威斯津 WGc-0201:HBV 相关晚期肝癌治疗性 mRNA
WestGene WGc-0201: therapeutic mRNA for HBV-related advanced HCC
NCT05738447
I 期 / Phase 1 n=12 无 DLT;可评估 10 人 DCR 约 70%,中位 PFS 2.6 月(ESMO 2025;开标 I 期探索终点,非确证效力)
n=12 no DLT; evaluable n=10 DCR ~70%, mPFS 2.6 mo (ESMO 2025; open-label Phase 1 exploratory, not confirmatory efficacy)
ESMO 摘要 / ESMO abstract
2025-07-31 IAVI/Moderna mRNA-1644:HIV eOD-GT8 germline 靶向(G002/G003)
IAVI/Moderna mRNA-1644: HIV eOD-GT8 germline targeting (G002/G003)
Science
I 期读出 / Phase 1 readout 约 94% 诱导 VRC01 类 bnAb 前体;皮肤 AE 约 18%、荨麻疹约 12%;无感染保护终点
~94% induced VRC01-class bnAb precursors; skin AE ~18%, urticaria ~12%; no infection-prevention endpoint
Science 2025
2025-01-01 HVTN 302:HIV BG505 三聚体 mRNA(Moderna 代工)
HVTN 302: HIV BG505 trimer mRNA (Moderna-manufactured)
Sci Transl Med
I 期读出 / Phase 1 readout 膜锚定三聚体约 80% 产生自体 tier-2 中和 Ab;荨麻疹约 7%;无现场效力
Membrane-anchored trimer ~80% autologous tier-2 nAb; urticaria ~7%; no field efficacy
Sci Transl Med

动物实验 Animal studies

首批方向:部分重编程 + 衰老细胞清除 First tracks: partial reprogramming + senolytics

左右滑动查看Swipe to see more

更新日期
Updated
项目简介
Project
状态
Status
最新进展
Latest
证据
Evidence
2026-07-01 长期 D+Q 对自然衰老小鼠肾脏的多组学评估
Long-term D+Q multi-omics of naturally aged mouse kidney
npj Regen Med
衰老细胞清除 / Senolytic 降低 p16/p21 与纤维化炎症,恢复 Klotho,重塑肾小管通讯与脂质代谢
Lowered p16/p21 and fibro-inflammation; restored Klotho; remodeled tubular communication & lipid metabolism
npj Regenerative Medicine
2026-06-17 老年小鼠多组织单细胞图谱解析 D+Q 疗效与干预时机
Aged-mouse multi-tissue scRNA atlas of D+Q efficacy and timing
Nature Aging
衰老细胞清除 / Senolytic 免疫、纤维化与代谢读数改善;早启动、长疗程优于晚而短的干预
Immune, fibrosis & metabolic readouts improved; early/long beats late/short
Nature Aging
2026-02-10 EPFL:OSK 基因治疗靶向记忆痕迹神经元做部分重编程
EPFL: OSK gene therapy targeting engram neurons for partial reprogramming
Neuron
部分重编程 / Partial reprogramming 老年与阿尔茨海默模型小鼠学习记忆显著改善,接近年轻对照;纠正突触可塑性相关表观转录异常
Aged & AD-model mice: learning/memory markedly improved, near young controls; corrected synaptic plasticity epi-transcriptomic deficits
Neuron
2026-01-27 化学鸡尾酒 7c 在 UM-HET3 小鼠的体内部分重编程安全性
Chemical cocktail 7c in vivo partial-reprogramming safety in UM-HET3 mice
Aging Cell
部分重编程 / Partial reprogramming 安全剂量未降肝肾转录组年龄;高剂量致体重骤降、脂滴堆积与线粒体应激
Safe dose did not lower liver/kidney transcriptomic age; high dose caused weight drop, lipid droplets & mito stress
Aging Cell
2024-09-11 Altos/Belmonte:Cdkn2a 启动子驱动 OSK,仅重编程衰老/应激细胞
Altos/Belmonte: Cdkn2a-driven OSK reprogramming only senescent/stressed cells
Sci Transl Med
部分重编程 / Partial reprogramming 早衰与自然衰老小鼠延寿、炎症下降、伤口愈合改善,肿瘤发生率未见升高
Progeria & naturally aged mice: lifespan↑, inflammation↓, wound healing↑; no rise in tumor incidence
Science Translational Medicine
2022-03-07 Salk 等:长期周期 OSKM 部分重编程作用于生理衰老小鼠
Salk et al.: cyclic long-term OSKM partial reprogramming in physiologically aged mice
Nature Aging
部分重编程 / Partial reprogramming 肾、皮肤等多组织年轻化,表观时钟回拨;疗程越长获益越大
Multi-tissue rejuvenation (kidney, skin, etc.); epigenetic clocks rewind; longer cycles, larger gains
Nature Aging
2020-12-02 Sinclair:AAV2-OSK 玻璃体腔递送恢复视网膜年轻表观信息(ER-100 临床前根基)
Sinclair: AAV2-OSK intravitreal restoration of youthful retinal epigenetic information (ER-100 preclinical basis)
Nature
部分重编程 / Partial reprogramming 青光眼与老年小鼠视功能改善,视神经轴突可再生,长期表达未见视网膜肿瘤
Glaucoma & aged mice: vision improved, optic axons regenerable; long-term expression no retinal tumors seen
Nature
2018-07-09 Mayo Clinic:间歇口服 D+Q 用于自然衰老小鼠体能与生存
Mayo Clinic: intermittent oral D+Q for fitness & survival in naturally aged mice
Nature Medicine
衰老细胞清除 / Senolytic 改善体能;24-27 月龄起治可使治疗后生存期延长约 36%
Improved fitness; starting at 24-27 mo extended post-treatment survival ~36%
Nature Medicine
2015-03-09 首次系统筛选达沙替尼+槲皮素(D+Q)为选择性清除衰老细胞组合
First systematic screen identifying dasatinib+quercetin (D+Q) as selective senolytic combo
Aging Cell
衰老细胞清除 / Senolytic 老年小鼠体内衰老标志下降,奠定后续 D+Q 动物与人体试验基础
Lowered senescence markers in aged mice; foundation for later D+Q animal & human trials
Aging Cell